Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D09TXU
|
||||
Former ID |
DIB008763
|
||||
Drug Name |
DT-831j
|
||||
Synonyms |
DT-831j; Factor Xa antagonists, Daiichi Sankyo
|
||||
Indication | Thrombosis [ICD9: 437.6, 453, 671.5, 671.9; ICD10:I80-I82] | Investigative | [1], [2] | ||
Company |
Daiichi Sankyo Co Ltd
|
||||
Structure |
![]() |
Download2D MOL |
|||
Canonical SMILES |
C(C)(C)(Oc1ccc(NC(=O)c2[nH]c3c(c2)cc(cc3)Cl)c(NC(=O)c2s<br />c3c(n2)CCN(C3)C)c1)C(=O)O
|
||||
Target and Pathway | |||||
Target(s) | Coagulation factor Xa | Target Info | Antagonist | [1], [2] | |
KEGG Pathway | Complement and coagulation cascades | ||||
PANTHER Pathway | Blood coagulation | ||||
Pathway Interaction Database | Beta2 integrin cell surface interactions | ||||
PathWhiz Pathway | Coagulation | ||||
Reactome | Extrinsic Pathway of Fibrin Clot Formation | ||||
Intrinsic Pathway of Fibrin Clot Formation | |||||
Common Pathway of Fibrin Clot Formation | |||||
Gamma-carboxylation of protein precursors | |||||
Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus | |||||
Removal of aminoterminal propeptides from gamma-carboxylated proteins | |||||
WikiPathways | Complement and Coagulation Cascades | ||||
Human Complement System | |||||
PTM: gamma carboxylation, hypusine formation and arylsulfatase activation | |||||
Blood Clotting Cascade | |||||
Formation of Fibrin Clot (Clotting Cascade) | |||||
References | |||||
REF 1 | Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer. 2011 Apr 1;117(7):1334-49. | ||||
REF 2 | Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.